Abstract
Subgroup analysis of phase 3 study of fixed-dose combination of dapagliflozin, glimepiride and metformin IR in type 2 diabetes mellitus patients aged <45 years and 45 to 65 years
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have